Navigation Links
Taber's Cyclopedic Medical Dictionary, 20th Ed.

ProductsTaber's Cyclopedic Medical Dictionary, 20th Ed.
Company Skyscape, Inc.
Item Taber's Cyclopedic Medical Dictionary, 20th Ed.
Features 
  • 56,000 definitions
  • More than 6,000 revised terms
  • Almost 700 illustrations and full color images
  • 100 more Patient Care sections
  • Cautions statements added to almost 350 terms
  • Appendices including nutrition and complementary medicine
  • Improved placement of multi-word entries
  • 30,000 pronunciations of new and current terms
Description With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information.
Info Skyscape, Inc.
Customer Service: 508-460-6500
Web site: http://www.skyscape.com/index/home.aspx

Related medicine products :

1. Tabers Medical Dictionary, 20th ed.
2. Tabers Cyclopedic Medical Dictionary
3. Tabers Cyclopedic Medical Dictionary 20th edition
4. Disposable Medical Penlight
5. MaximEyes Practice Management and Electronic Medical Records Software Solutions
6. Sony LMD-181MD Medical Grade LCD
7. Sony LMD-151MD Medical Grade LCD
8. Sony PVM-20M2MDU Medical Grade Monitor
9. Sony PVM-14M2MDU Medical Grade Monitor
10. PRAXIS® Electronic Medical Records v. 2.19
11. TTI Medical Digital Video Disk Recorder
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products:
(Date:12/3/2008)... SAN FRANCISCO, Dec. 3 ... its annual High School Student Symposium at the S...8, beginning at 8:00 a.m. PST. The symposium, whic...ical sciences, and medical research, is held in co...This year, students will have the opportunity to e...
(Date:12/3/2008)... SAN FRANCISCO, Dec. 3 ...d,s largest professional society of blood speciali...of Representatives and the Deputy Director of the ...for their efforts to promote biomedical research. ...junction with the Society,s 50th Annual Meeting in...
(Date:12/3/2008)... MOUNT LAUREL, N.J., Dec. 3 MedQui...nscription Service Organization (MTSO) in the worl...of several material legal matters , , Reso...viously announced, the Company received an adminis...ed States Department of Justice ("DOJ") on Decembe...
(Date:12/3/2008)..., ROCHESTER, Minn. - A new Mayo Clinic study foun...ngest when they underwent aggressive surgeries to ...moving the entire tumor was not possible, patients...llowed by radiation therapy. This study is availab...logy ( http://neuro-oncology.dukejournals.org/cgi...
Breaking Medicine News(10 mins):Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2
...chers are now saying that the gene known as “might...ll. Studies on this gene arose when a German neuro...have especially well-developed muscles. Further te...tatin gene that effectively kept his body from pro...
...as been found to boost the immune system and help ...ed supplements to determine their effect on childr... and they say that a simple zinc supplement can h...er quicker . The study involved 270 children betwe...
...liver failure is the loss of liver function that c... treatment consists of intensive supportive care i...e liver might recover spontaneously // or a donor ...ation. About 80 percent of patients will die unles...
...chers say they discovered an anti-viral drug that ...s B virus in women who are being treated with chem... // of breast cancer patients carry the hepatitis ...ing HBV reactivation during chemotherapy, which is...
Other Medicine News:
(Date:12/1/2008)...Newswire/ -- S*BIO Pte Ltd today announced the ini... potent and orally-active JAK2 inhibitor, in leadi...chronic idiopathic myelofibrosis (CIMF). , ,...d tolerability of SB1518 in patients with CIMF and...e 1 part of the study will assess the safety profi...
(Date:12/1/2008)...till the best policy , , ROCHESTER, Minn.,...m Mayo Clinic finds the use of the drug therapy et...is, an acute inflammation of the liver caused by e...e study are published in the December issue of Ga... , , VIDEO ALERT: Additional audio and vid...
(Date:12/1/2008)...wswire-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulle...ompany developing,human vaccines for diseases cau...ther infectious agents, announced today that the l...ake place in twelve sites across North and South A...on with The National Institutes of,Health (NIH), ...
(Date:11/28/2008)..., November 28 German biotech compa...pecialized HIV monitoring and,AIDS patient follow...ies. In,the year 2008, 2.5 million patient tests ... highly affordable "CyFlow" system, supporting alr...IDS. Due to introduction of the,Partec innovation...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Water purification down the nanotubes 7695 1Water purification down the nanotubes 7695 2Micromet Inc Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 7693 1Micromet Inc Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 7693 2Micromet Inc Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 7693 3Micromet Inc Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 7693 4AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease 3056 1AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease 3056 2AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease 3056 3AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease 3056 4Symmetry Medical to Present at UBS Global Life Sciences Conference 7690 1Symmetry Medical to Present at UBS Global Life Sciences Conference 7690 2
...ounces Positive Top-Line Phase III Results for,Kep...eizures in,Paediatric Patients from One Month to L...pril 20, 2007 - UCB today announced,positive top-l...ized, multi-centre, placebo-controlled study evalu... (levetiracetam) (20-50,mg/kg/day) as adjunctive t...
...-(BUSINESS WIRE)--Apr 19, 2007 - Gilead Sciences, ...s of its Phase III,AIR-CF2 study evaluating aztreo...nts with cystic fibrosis (CF) who have,pulmonary P...y, a,28-day treatment course of aztreonam lysine s... or intravenous (IV) antibiotics versus,placebo. A...
Other Medicine Technology:UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7